Oral Treatment With α-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy
Top Cited Papers
Open Access
- 1 November 2006
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 29 (11), 2365-2370
- https://doi.org/10.2337/dc06-1216
Abstract
OBJECTIVE—The aim of this trial was to evaluate the effects of α-lipoic acid (ALA) on positive sensory symptoms and neuropathic deficits in diabetic patients with distal symmetric polyneuropathy (DSP). RESEARCH DESIGN AND METHODS—In this multicenter, randomized, double-blind, placebo-controlled trial, 181 diabetic patients in Russia and Israel received once-daily oral doses of 600 mg (n = 45) (ALA600), 1,200 mg (n = 47) (ALA1200), and 1,800 mg (ALA1800) of ALA (n = 46) or placebo (n = 43) for 5 weeks after a 1-week placebo run-in period. The primary outcome measure was the change from baseline of the Total Symptom Score (TSS), including stabbing pain, burning pain, paresthesia, and asleep numbness of the feet. Secondary end points included individual symptoms of TSS, Neuropathy Symptoms and Change (NSC) score, Neuropathy Impairment Score (NIS), and patients’ global assessment of efficacy. RESULTS—Mean TSS did not differ significantly at baseline among the treatment groups and on average decreased by 4.9 points (51%) in ALA600, 4.5 (48%) in ALA1200, and 4.7 (52%) in ALA1800 compared with 2.9 points (32%) in the placebo group (all P < 0.05 vs. placebo). The corresponding response rates (≥50% reduction in TSS) were 62, 50, 56, and 26%, respectively. Significant improvements favoring all three ALA groups were also noted for stabbing and burning pain, the NSC score, and the patients’ global assessment of efficacy. The NIS was numerically reduced. Safety analysis showed a dose-dependent increase in nausea, vomiting, and vertigo. CONCLUSIONS—Oral treatment with ALA for 5 weeks improved neuropathic symptoms and deficits in patients with DSP. An oral dose of 600 mg once daily appears to provide the optimum risk-to-benefit ratio.Keywords
This publication has 30 references indexed in Scilit:
- Long-Term Effects of Ranirestat (AS-3201) on Peripheral Nerve Function in Patients With Diabetic Sensorimotor PolyneuropathyDiabetes Care, 2006
- Irbesartan and Lipoic Acid Improve Endothelial Function and Reduce Markers of Inflammation in the Metabolic SyndromeCirculation, 2005
- Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetesDiabetic Medicine, 2004
- The Sensory Symptoms of Diabetic Polyneuropathy Are Improved With α-Lipoic AcidDiabetes Care, 2003
- Effects of alpha-lipoic acid on microcirculation in patients with peripheral diabetic neuropathyExperimental and Clinical Endocrinology & Diabetes, 2000
- The Effect of α-Lipoic Acid on the Neurovascular Reflex Arc in Patients with Diabetic Neuropathy Assessed by Capillary MicroscopyMicrovascular Research, 1999
- α-lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuriaFree Radical Biology & Medicine, 1999
- Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (α-lipoic acid): A two year multicenter randomized double-blind placebo-controlled trial (ALADIN II)Free Radical Research, 1999
- α-Lipoic acid reduces expression of vascular cell adhesion molecule-1 and endothelial adhesion of human monocytes after stimulation with advanced glycation end productsClinical Science, 1999
- Detection, characterization, and staging of polyneuropathy: Assessed in diabeticsMuscle & Nerve, 1988